What Is Latent TB? Symptoms, Diagnosis, and Treatment

Latent tuberculosis infection, often shortened to latent TB or LTBI, is a condition in which the bacterium Mycobacterium tuberculosis lives inside your body but is held in check by your immune system. You have no symptoms, you feel perfectly well, and you cannot spread TB to anyone else. Yet the bacteria are not gone. Roughly one in four people worldwide carry this silent infection, and without treatment, a fraction of them will eventually develop active, contagious TB disease.

How Latent TB Differs from Active TB

The formal definition of LTBI is a state of persistent immune response to M. tuberculosis antigens without any clinical evidence of active disease.¹ In practical terms, that means the bacteria entered your lungs at some point, your immune system recognized the threat, and special immune cells walled the bacteria off inside tiny clusters called granulomas. Immune signaling molecules, particularly interferon-gamma and TNF-alpha, help keep those granulomas sealed and the bacteria dormant.²

Active TB is what happens when that containment fails. The bacteria begin multiplying, the granulomas break down, and the person develops a persistent cough, fevers, night sweats, weight loss, and sometimes coughing up blood. Active TB shows up on chest X-rays, can be confirmed by culturing the bacteria from sputum, and is transmissible through the air. Latent TB produces none of these signs. You could carry it for decades without ever knowing. The distinction matters enormously: active TB needs aggressive multi-drug treatment for months, while latent TB can be addressed with shorter, simpler regimens aimed at prevention.

How Common Is Latent TB

A systematic review and meta-analysis drawing on surveys worldwide estimated that about a quarter of the global population has LTBI, with the prevalence sitting at roughly 24.8% based on blood-test surveys and about 21% based on skin-test surveys.³ A modeling study placed the total number of people infected at about 1.7 billion as of 2014, with the heaviest burden concentrated in the WHO Southeast Asia, Western Pacific, and Africa regions, which together account for around 80% of all latent infections. China and India alone were estimated to harbor roughly 350 million infections each.⁴

The good news is that LTBI prevalence has been declining. Between 1990 and 2019, the global rate fell from about 31% to about 24%, with the steepest drops in the European region.⁵ Still, the sheer scale of the reservoir means that even a small percentage reactivating each year translates into millions of new active TB cases.

Why Some People’s Latent TB Reactivates

Most people with LTBI never develop active disease. The commonly cited lifetime risk of reactivation for an otherwise healthy person is around 5 to 10 percent. But certain conditions tilt the odds dramatically. The most significant risk factor is HIV infection, because HIV attacks the very immune cells responsible for keeping TB bacteria penned in. A study comparing people living with HIV to HIV-negative individuals in Lithuania found that HIV-positive participants had a substantially higher rate of LTBI, and that factors such as injecting drug use and a history of imprisonment independently increased the odds of carrying latent infection.⁶ Among HIV-negative individuals, a history of close contact with someone who had active TB was the strongest predictor.

Beyond HIV, other conditions that weaken the immune system raise reactivation risk: organ transplantation and the anti-rejection drugs that follow, TNF-alpha inhibitors used for autoimmune diseases like rheumatoid arthritis and Crohn’s disease, poorly controlled diabetes, chronic kidney disease requiring dialysis, and certain cancers. People who are malnourished, very young children, and older adults are also more vulnerable. These are the groups for whom screening and preventive treatment matter most.

Diagnosis Without Symptoms

Because latent TB causes no symptoms, diagnosing it relies entirely on detecting your immune system’s memory of exposure. Two types of tests are used, and they measure fundamentally different things about that immune memory.

The Tuberculin Skin Test

The skin test, sometimes called the Mantoux test, involves injecting a small amount of purified protein derivative (PPD) from TB bacteria under the skin of your forearm. You return two to three days later, and a health worker measures any firm, raised bump that forms. The bump reflects a delayed immune reaction: if your body has encountered TB before, immune cells gather at the injection site and cause swelling. The test has been in use for over a century, dating back to Florence Seibert’s work purifying tuberculin in the early twentieth century.⁷

The skin test is cheap and widely available, but it has a well-known Achilles’ heel: it cross-reacts with the BCG vaccine and with some environmental mycobacteria. If you received a BCG vaccination as a child, which billions of people outside the United States and parts of Western Europe have, you may test positive even though you were never infected with actual TB. One study of BCG-vaccinated health care workers found that more than half of those with a positive skin test had a negative result on a more specific blood test, meaning their skin-test positivity was likely a leftover from vaccination rather than true infection.⁸

Interferon-Gamma Release Assays

IGRAs are blood tests that measure how your immune cells respond to proteins unique to M. tuberculosis, proteins that do not appear in the BCG vaccine strain or in most environmental mycobacteria. The two main commercial IGRAs are QuantiFERON-TB Gold and T-SPOT.TB. Because they target TB-specific antigens, they are not thrown off by prior BCG vaccination the way the skin test is.

A systematic review and meta-analysis comparing the two approaches for TB diagnosis found that IGRAs had a sensitivity of about 79% and a specificity of about 86%, while the skin test came in at roughly 72% sensitivity and 79% specificity.⁹ A latent-class analysis looking specifically at latent TB diagnosis found that the specificity advantage of IGRAs was especially pronounced in BCG-vaccinated populations: the QuantiFERON test maintained a specificity above 93% regardless of vaccination history, while the skin test’s specificity dropped to around 79% in vaccinated people.¹⁰

Neither test, however, can tell you whether your latent infection will ever progress to active disease. That is the central frustration of LTBI diagnosis: the tests confirm exposure and immune memory, but they say nothing about your personal timeline of risk.⁷

The BCG Vaccination Complication

BCG is one of the most widely administered vaccines in history, given at birth in many countries to protect against severe childhood TB. It does offer real protection against LTBI progressing to active disease. A meta-analysis found that people who had received BCG had about a 43% lower risk of their latent infection becoming active TB, and the protective effect was stronger in children under 15 and in countries with low TB incidence.¹¹

The complication is diagnostic, not medical. In BCG-vaccinated children, the skin test’s specificity can drop below 30%, meaning it flags the majority of vaccinated children as positive even when they are not truly infected.¹² This creates a real problem in countries where BCG coverage is high and TB screening relies on the skin test. IGRA blood tests help sort out who is truly infected, but they cost more, require a blood draw and laboratory processing, and are less available in resource-limited settings. In practice, many clinicians in high-BCG-coverage countries now use the skin test as a first step and confirm positives with an IGRA.

Treatment Options for Latent TB

Treating latent TB is preventive: the goal is to kill dormant bacteria before they have a chance to wake up. Several regimens are available, and the evidence is clear that shorter courses are just as effective as longer ones while being far easier for people to complete.

The traditional regimen is daily isoniazid for nine months. It works, but fewer people finish it. A retrospective study found that only about 52% of patients completed nine months of isoniazid, compared to 85% who completed either three months of weekly isoniazid plus rifapentine (called 3HP) or four months of daily rifampin.¹³ A network meta-analysis confirmed that regimens lasting three to four months had completion rates roughly 12 percentage points higher than six months of isoniazid, and that the 3HP and four-month rifampin regimens ranked highest for treatment completion.¹⁴

In terms of preventing active TB, all the standard regimens perform comparably. A separate network meta-analysis found that every active regimen except the nine-month isoniazid course showed a statistically significant benefit over placebo, and head-to-head comparisons between active regimens did not reveal meaningful differences in effectiveness.¹⁵ The nine-month course likely underperformed in real-world settings not because the drug itself was weaker, but because so many people stopped taking it before finishing.

Side Effects and Liver Toxicity

Isoniazid is the drug most associated with liver problems during LTBI treatment. One study at a TB center found that roughly one in five patients on isoniazid developed clinically significant liver injury, and that people with dyslipidemia were at particularly high risk, with about eight times the odds of liver damage.¹⁶ Men were also more likely to be affected.

Rifampin-based regimens appear gentler on the liver. A retrospective study in patients with chronic liver disease found that six months of isoniazid carried about seven times the odds of drug-induced liver injury compared to four months of rifampin. Liver injury was also independently linked to patients not finishing treatment, which makes the side-effect profile a practical concern beyond just discomfort.¹⁷ For people who already have liver disease or who take other medications that stress the liver, rifampin-based regimens are often preferred. Regardless of regimen, periodic blood tests to monitor liver function are standard practice during LTBI treatment, especially for older adults, people who drink alcohol regularly, and those on other hepatotoxic medications.

Latent TB in Children

Children face a unique set of challenges with latent TB. Young children who are infected are more likely than adults to progress to active disease, and active TB in young children can be rapidly serious, spreading beyond the lungs more readily. That makes finding and treating LTBI in children a priority.

Diagnosis in children is trickier. In a study of over 200 children, there was excellent agreement between negative skin tests and negative IGRA results, but only 23% of children with a positive skin test also tested positive on the QuantiFERON blood test. The discrepancy was largely attributed to prior BCG vaccination generating false positives on the skin test.¹⁸ Children with known recent exposure to someone with active TB produced stronger IGRA responses, reinforcing the blood test’s usefulness for identifying true infection.

Treatment-wise, a randomized clinical trial in children aged 2 to 17 found that the three-month combination of rifapentine and isoniazid (3HP) was as effective as isoniazid alone in preventing active TB, with a higher completion rate and a good safety profile.¹⁹ The shorter course is especially helpful for children, whose families may struggle to maintain a daily pill routine for nine months.

When the Source Case Had Drug-Resistant TB

One of the most worrying scenarios is when you’ve been exposed to someone whose TB was resistant to the standard first-line drugs, particularly multidrug-resistant TB (MDR-TB), which does not respond to both isoniazid and rifampin. Until recently, there was no proven preventive regimen for contacts of MDR-TB patients. Clinicians could either offer no treatment or try off-label use of fluoroquinolone antibiotics based on limited observational data.

That changed with two randomized trials demonstrating that six months of daily levofloxacin in household contacts of people with MDR-TB was safe and effective at preventing active TB. Based on those results, the WHO updated its guidelines to make a strong recommendation for levofloxacin as preventive therapy in this setting.²⁰ This is a meaningful advance for an area of TB prevention that had been a blind spot for decades.

Why People Do Not Finish Treatment

Even the shorter regimens face adherence challenges, and understanding why matters because an incomplete course of preventive treatment leaves you largely unprotected. A qualitative study within a large health system in Southern California explored the barriers patients reported. Many described difficulty fitting daily pills into their routine, especially if they had never taken long-term medication before. Managing interactions with other prescriptions added complexity. Some patients simply lost motivation over time, since they felt perfectly healthy and the threat they were treating was invisible.²¹

The psychological dimension goes beyond logistics. A systematic review found that people diagnosed with LTBI often experienced fear, anxiety, and stigma. Some were reluctant to disclose their diagnosis, especially pregnant women. The emotional burden was sometimes more significant than any physical symptoms from the medication, particularly among people who were not well informed about the difference between latent and active TB.²² Confusing “you have TB bacteria in your body” with “you have TB disease” is a common misunderstanding, and it can make the diagnosis feel far more alarming than it needs to be.

Whether Screening and Treatment Are Worth the Cost

Given that most people with LTBI will never get sick, you might wonder whether the resources spent on finding and treating them are justified. The economic evidence strongly says yes, particularly for high-risk groups. A cost-effectiveness analysis of screening healthcare workers in Sri Lanka found an incremental cost of about $2,381 per disability-adjusted life-year averted, well within the threshold most health systems consider cost-effective.²³ A modeling study comparing different preventive treatment regimens at the community level found that all five regimens studied were cost-effective compared to no treatment, with costs per quality-adjusted life-year gained ranging from as low as $154 for a three-month course of rifampin plus isoniazid up to $910 for nine months of isoniazid.²⁴

The logic is straightforward: treating one case of active TB is vastly more expensive than treating latent TB, and active cases can generate additional infections that create still more costs. Preventing even a relatively small number of reactivations can save a health system significant money and spare patients months of difficult treatment.

Emerging Tools for Predicting Who Will Get Sick

The biggest gap in LTBI management is the inability to predict which infected individuals will eventually develop active disease. Current tests tell you someone has been exposed, but they cannot distinguish the person whose immune system will maintain control for a lifetime from the person headed for reactivation within a few years. Researchers are working to close that gap through biomarker discovery.

Studies have found that certain blood-based signatures, including patterns in gene expression and specific T-cell subtypes, differ between people with stable LTBI and those who later develop active TB. Some of these signatures were detectable more than a year before a clinical diagnosis of active disease.²⁵ The categories of markers being explored span a wide range: gene-expression profiles, protein levels, metabolic signatures, immune-cell counts, and antibody responses.²⁶

If a reliable prognostic test makes it to clinical practice, it could transform how LTBI is managed. Instead of treating everyone who tests positive for latent infection, or trying to guess based on rough risk categories, clinicians could target treatment to the small fraction of people whose biomarkers signal genuine danger. That would reduce unnecessary medication, cut side effects, and concentrate resources where they are most likely to prevent actual disease. None of these biomarker tests are ready for routine use yet, but the pace of research suggests that the era of treating LTBI largely in the dark may not last much longer.